SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis SinoMab BioScience Limited Apr 09, 2025 14:49 HKT/SGT Read More
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities NEC Corporation Apr 01, 2025 15:15 HKT/SGT Read More
エーザイ、アルツハイマー・パーキンソン病学会において、レカネマブの長期実臨床データやバイオマーカーをはじめとするアルツハイマー病の最新成果を発表 Eisai Mar 27, 2025 08:40 JST Read More
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards Eisai Mar 25, 2025 16:28 HKT/SGT Read More
エーザイ、日本発 世界初の早期アルツハイマー病治療剤「レケンビ」が第 12 回技術経営・イノベーション大賞において「内閣総理大臣賞」を受賞 Eisai Mar 25, 2025 15:30 JST Read More
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace Eisai Mar 25, 2025 11:21 HKT/SGT Read More
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce Hua Medicine Mar 18, 2025 22:36 HKT/SGT Read More
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time Eisai Mar 10, 2025 19:24 HKT/SGT Read More
CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI NEC Corporation Mar 10, 2025 11:10 HKT/SGT Read More
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan Eisai Mar 05, 2025 08:09 HKT/SGT Read More
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia Eisai Mar 04, 2025 16:22 HKT/SGT Read More
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" Eisai Mar 03, 2025 14:41 HKT/SGT Read More
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease Eisai Mar 03, 2025 12:53 HKT/SGT Read More
